Current and emerging therapeutic options for the management of functional dyspepsia
Autor: | A. Vandenberghe, Imke Masuy, Jan Tack, Jolien Schol, Florencia Carbone, K Van den Houte |
---|---|
Rok vydání: | 2020 |
Předmět: |
medicine.medical_specialty
medicine.medical_treatment Prokinetic agent Organic disease Epigastric pain Gastroenterology 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Internal medicine medicine Humans Pharmacology (medical) Dyspepsia Pharmacology business.industry Syndrome General Medicine Postprandial Period Abdominal Pain Thiazoles Distress chemistry 030220 oncology & carcinogenesis Acotiamide Benzamides business 030217 neurology & neurosurgery |
Zdroj: | Expert Opinion on Pharmacotherapy. 21:365-376 |
ISSN: | 1744-7666 1465-6566 |
DOI: | 10.1080/14656566.2019.1707805 |
Popis: | Introduction: Functional Dyspepsia (FD), defined as chronic symptoms originating from the gastroduodenal region in absence of readily identifiable organic disease, is one of the most common gastrointestinal disorders. FD is divided into two subgroups: Post-Prandial Distress Syndrome (PDS) or meal-related FD, characterized by postprandial fullness and early satiation, and Epigastric Pain Syndrome (EPS) or meal-unrelated FD, characterized by epigastric pain and burning.Areas covered: This review summarizes the existing and off-label therapeutic options for FD.Expert opinion: The identification of mechanisms, the Rome IV classification, the reduction of PDS/EPS overlap and pictograms for symptom identification allow a better diagnosis and a more targeted treatment choice. Acotiamide, a first-in-class prokinetic agent available only in Japan and India, is the only agent of proven efficacy for FD, but clinicians use acid-suppressive therapy, prokinetics, neuromodulators and herbal therapies for treating FD symptoms. New emerging targets are duodenal low-grade inflammation with eosinophils and duodenal or other modified luminal microbiota. |
Databáze: | OpenAIRE |
Externí odkaz: |